RSV Seasonal Vaccine Introduction and Growth Strategy
68 potential new vaccines and medicines in pipeline
Phase III / Registration – 17 assets
Arexvy (RSV vaccine)
gepotidacin (2140944)
bepirovirsen (3228836)
Bexsero (MenB vaccine)
MenABCWY vaccine (3536819)
tebipenem pivoxil (3778712)
ibrexafungerp (5458448)
Nucala (mepolizumab)
depemokimab (3511294)
latozinemab (4527223)
camlipixant (5464714)
momelotinib (3070785)
Jemperli (dostarlimab)
Zejula (niraparib)
Blenrep (belantamab mafodotin)
cobolimab (4069889)
linerixibat (2330672)
Recombinant protein, adjuvanted*
BTI inhibitor*
Antisense oligonucleotide*
Recombinant protein, OMV
Recombinant protein, OMV, conjugated vaccine
Antibacterial carbapenem*
Antifungal glucan synthase inhibitor*
Anti-IL5 antibody
Long-acting anti-IL5 antibody*
Anti-sortilin antibody*
P2X2/P2X3 receptor antagonist*
JAK1, JAK2 and ACVR1 inhibitor*
Anti-PD-1 antibody*
PARP inhibitor*
Anti-BCMA ADC*
Anti-TIM-3 antibody*
IBAT inhibitor
RSV older adults^8
Uncomplicated UTI**
Hepatitis B virus**
Meningitis B (infants US)
MenABCWY, 1st Gen
Complicated UTI⁹
Invasive candidiasis
COPD
Asthma**
Frontotemporal dementia 10**
Refractory chronic cough
Myelofibrosis^
Endometrial cancer^**
Ovarian cancer**
Multiple myeloma
Non-small cell lung cancer
Cholestatic pruritus in primary biliary cholangitis
Infectious diseases
HIV (VIIV)
Respiratory/Immunology
Oncology
Opportunity driven
GSK
*In-license or other alliance relationship with third party
**
Additional indications or candidates also under investigation In registration
1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. GSK has an exclusive global license option to co-develop and commercialise the candidate 4. Imminent study start 5. GSK has
exclusive option to co-develop post phase II 6. Phase II/III study start expected in 2023 7. Phase II study start expected in 2023 8. Approved in US and EU 9. Phase III study start expected in 2023 10. Phase III trial in patients
with progranulin gene mutation
39View entire presentation